Advertisement

HindustanTimes Sun,21 Dec 2014

Another firm in patent war, appeals to HC

HT Correspondent, Hindustan Times  New Delhi, April 02, 2013
First Published: 23:05 IST(2/4/2013) | Last Updated: 01:43 IST(3/4/2013)

Merck Sharp and Dohme (MSD) has approached the Delhi High Court against Mumbai-based Glenmark Pharmaceuticals alleging patent violation of its anti-diabetes drug Januvia and Janumet.

Advertisement

The development comes a day after the landmark judgment by Supreme Court rejecting patent protection for Novartis AG’s anti-cancer drug Glivec.

“We are disappointed in Glenmark’s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them,” said MSD spokesperson.

“Strong intellectual property protection is essential for growing India’s innovative capacity and economic growth.  As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines,” MSD added.

With Glenmark launching its generic version, the price of the drug will fall by 25-30%.

“Glenmark is a responsible company and has launched the products after due diligence and research,” the company said.


Advertisement
more from New Delhi

Delhi: Schools on alert after Peshawar

The terror attack that killed over 130 students in Pakistan’s Peshawar has jolted city schools into taking all possible measures to tighten security in and around their campus. Many schools reported a drop in attendance after the attack.
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved